Human RAGE. The bovine (Fig. 4A) and human (Fig. 4B) genes were sequenced by the dideoxy chain termination method. Potential N-linked glycosylation sites are indicated by boxed sequences, the putative polyadenylation sites are shown with bold underlining, and sequences matching the sequenced bovine peptides are indicated by light underlining. The following amino acid residues from the underlined peptide sequences were not determined by protein sequencing: all Cys (c) and Trp (W), Asn25 (N25) and Glu50 (E50). The bovine nucleotide sequence is SEQ ID No. 1. The bovine amino acid sequence is SEQ ID No. 2. The human nucleotide sequence is SEQ ID No. 3. The human amino acid sequence is SEQ ID No. 4.--

In the claims:

Please amend claims 1, 10, 13, 19, 27, 30 and 34 as follows:

--1.(amended) A method to prevent accelerated atherosclerosis in a subject predisposed thereto which comprises administering to the subject a polypeptide derived from soluble receptor for advanced glycation endproduct (SEQ ID NO.: 2 or 4) in an amount effective to prevent accelerated atherosclerosis in the subject, wherein the polypeptide inhibits an interaction between AGE and cellular RAGE.--

--10.(amended) The method of claim 1, wherein the polypeptide comprises [at least] a portion of ~~naturally-occurring~~ soluble receptor for advanced glycation endproduct.--

--13.(amended) The method of claim 1, wherein the polypeptide comprises a sequence [less than or equal] from 3 to 20 amino acids in length which sequence is

within the sequence of the naturally occurring soluble receptor for advanced glycation endproduct.--

--19.(amended) A method to prevent a macrovessel disease in a subject predisposed thereto which comprises administering to the subject a polypeptide derived from soluble receptor for advanced glycation endproduct (SEQ ID NO.: 2 or 4) in an amount effective to prevent macrovessel disease in the subject wherein the polypeptide inhibits an interaction between AGE and cellular RAGE.--

--27.(amended) The method of claim 17, wherein the polypeptide comprises [at least] a portion of ~~naturally occurring~~ soluble receptor for advanced glycation endproduct.--

--30.(amended) The method of claim 17, wherein the polypeptide comprises [less than or equal] from 3 to 20 amino acids in length which sequence is within the sequence of the ~~naturally occurring~~ soluble receptor for advanced glycation endproduct.

--34.(amended) The method of claim 19, wherein the [sRAGE] polypeptide is administered daily.--

REMARKS

Claims 1-35 are pending. Applicants have amended claims 1, 10, 13, 19, 27, 30 and 34 to more particularly point out the presently claimed invention. Applicants maintain that these amendments raise no issue of new matter. Support for these amendments may be found inter alia in the specification. For example, support for "from 3 to 20 amino acids" may be found on